Literature DB >> 11403944

Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices.

I Niespodziany1, H Klitgaard, D G Margineanu.   

Abstract

The effect of the new antiepileptic drug levetiracetam (LEV; KEPPRA) on the neuronal high-voltage-activated (HVA) Ca(2+) current was investigated on pyramidal neurones, visually identified in the CA1 area of rat hippocampal slices. Nystatin-perforated patch clamp recordings were made under experimental conditions designed to study HVA Ca(2+) currents. The HVA current, activated by steadily increasing voltage-ramps, was reversibly eliminated by Cd(2+) and depressed by either nimodipine, or omega-Conotoxin GVIA. After 30 min perfusion of the slices with LEV 32 microM, the current decayed to 55+/-9% (mean+/-SEM; n=9) of the initial value, which is significantly (P<0.05, two-tailed t-test) lower than the rundown to 84+/-10% in a control group (n=10) of neurones. The limited, but significant depression of the neuronal HVA Ca(2+) current, produced by LEV at a clinically relevant concentration, might contribute to the antiepileptic action of the drug.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403944     DOI: 10.1016/s0304-3940(01)01884-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  41 in total

Review 1.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative meta-analysis.

Authors:  Georgia Tsaousi; Chryssa Pourzitaki; Spyridon Siafis; Athanassios Kyrgidis; Vasilios Grosomanidis; Dimitrios Kouvelas; Georgios Papazisis
Journal:  Eur J Clin Pharmacol       Date:  2019-11-25       Impact factor: 2.953

3.  Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.

Authors:  Rainer Surges; Kirill E Volynski; Matthew C Walker
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

Review 4.  GABAA receptors, anesthetics and anticonvulsants in brain development.

Authors:  Oliver Henschel; Keith E Gipson; Angelique Bordey
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-04       Impact factor: 4.388

5.  Combined administration of levetiracetam and valproic acid attenuates age-related hyperactivity of CA3 place cells, reduces place field area, and increases spatial information content in aged rat hippocampus.

Authors:  Jonathan Robitsek; Marcia H Ratner; Tara Stewart; Howard Eichenbaum; David H Farb
Journal:  Hippocampus       Date:  2015-07-14       Impact factor: 3.899

6.  Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus.

Authors:  Chun-Yao Lee; Chih-Chuan Chen; Horng-Huei Liou
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

7.  Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study.

Authors:  Pasquale Striano; Antonietta Coppola; Giovanni Vacca; Federico Zara; Vincenzo Brescia Morra; Giuseppe Orefice; Salvatore Striano
Journal:  J Neurol       Date:  2006-05-12       Impact factor: 4.849

Review 8.  Levetiracetam in childhood epilepsy.

Authors:  Alberto Verrotti; Ebe D'Adamo; Pasquale Parisi; Francesco Chiarelli; Paolo Curatolo
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 9.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

10.  Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures.

Authors:  Carol M Ulloa; Allen Towfigh; Joseph Safdieh
Journal:  Neuropsychiatr Dis Treat       Date:  2009-09-15       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.